Protein tyrosine phosphatases as potential therapeutic targets

Development (Basingstoke)

Volumn 57, Issue 1, 2014, Pages 1227-1246

  He, Rong Jun ^a   Yu, Zhi Hong ^a   Zhang, Ruo Yu ^a   Zhang, Zhong Yin ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

CD45 antigen; CDC25; drug target; Fas associated phosphatase 1; low molecular weight PTPs; lymphoid specific tyrosine phosphatase; mitogen activated protein kinase phosphatases; phosphatases of regenerating liver 1; protein tyrosine phosphatases; PTP1B; Src homology phosphotyrosyl phosphatase 2; striatal enriched tyrosine phosphatases

Indexed keywords

AMINO ACID; ANTIGEN; DRUG; PHOSPHATASE; PROTEIN;

PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; PHOSPHORYLATION; PROCEDURES;

ANIMALS; DRUG DISCOVERY; HUMANS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN TYROSINE PHOSPHATASES;

EID: 84908133543     PISSN: 10116370     EISSN: 14617072     Source Type: Journal    
DOI: 10.1038/aps.2014.80     Document Type: Review

References (277)

1. Sams-Dodd F. Target-based drug discovery: is something wrong?. Drug Discov Today 2005; 2: 139-47.
2. Overington JP, Al-Lazikani B, Hopkins AL. Opinion-How many drug targets are there? Nat Rev Drug Discov 2006; 12: 993-6.
3. Cohen P, Alessi DR. Kinase drug discovery - what's next in the field?. ACS Chem Biol 2013; 1: 96-104.
4. Hunter T. Protein-kinases and phosphatases - the yin and yang of protein-phosphorylation and signaling. Cell 1995; 2: 225-36.
5. Deng Y, Deng H, Zhu SL, Xu P, Shi ZY, Shan BL. Nature with Math Physics Yin Yang. J Math Med 1999; 1: 48-9.
6. Tonks NK, Neel BG. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol 2001; 2: 182-95.
7. Bialy L, Waldmann H. Inhibitors of protein tyrosine phosphatases: next-generation drugs?. Angew Chem Int Edit 2005; 25: 3814-39.
8. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006; 11: 833-46.
9. Julien SG, Dube N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 2011; 1: 35-49.
10. Tonks NK. Protein tyrosine phosphatases - from housekeeping enzymes to master regulators of signal transduction. FEBS J 2013; 2: 346-78.
11. He R, Zhang ZY. Current status of PTP-based therapeutics. In: Neel BG, Tonks NK, editors. Protein tyrosine phosphatases in cancer. New York: Cancer Research at Springer; 2014. in Press
12. Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, Godzik A, et al. Protein tyrosine phosphatases in the human genome. Cell 2004; 6: 699-711.
13. Li X, Oghi KA, Zhang J, Krones A, Bush KT, Glass CK, et al. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 2003; 6964: 247-54.
14. Van Huijsduijnen RH, Bombrun A, Swinnen D. Selecting protein tyrosine phosphatases as drug targets. Drug Discov Today 2002; 19: 1013-9.
15. Tonks NK, Diltz CD, Fischer EH. Purification of the major proteintyrosine- phosphatases of human-placenta. J Biol Chem 1988; 14: 6722-30.
16. Zhang ZY, Lee SY. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin Investig Drugs 2003; 2: 223-33.
17. Bandyopadhyay D, Kusari A, Kenner KA, Liu F, Chernoff J, Gustafson TA, et al. Protein-Tyrosine phosphatase 1B complexes with the insulin receptor in vivo and is tyrosine-phosphorylated in the presence of insulin. J Biol Chem 1997; 3: 1639-45.
18. Goldstein BJ, Bittner-Kowalczyk A, White MF, Harbeck M. Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-Tyrosine phosphatase 1B - Possible facilitation by the formation of a ternary complex with the GRB2 adaptor protein. J Biol Chem 2000; 6: 4283-9.
19. Kaszubska W, Falls HD, Schaefer VG, Haasch D, Frost L, Hessler P, et al. Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line. Mol Cell Endocrinol 2002; 1-2: 109-18.
20. Lund IK, Hansen JA, Andersen HS, Moller NPH, Billestrup N. Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling. J Mol Endocrinol 2005; 2: 339-51.
21. Ahmad F, Li PM, Meyerovitch J, Goldstein BJ. Osmotic loading of neutralizing antibodies demonstrates a role for protein-Tyrosinephosphatase 1b in negative regulation of the insulin action pathway. J Biol Chem 1995; 35: 20503-8.
22. Zhang S, Zhang ZY. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today 2007; 9-10: 373-81.
23. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999; 5407: 1544-8.
24. Haj FG, Zabolotny JM, Kim YB, Kahn BB, Neel BG. Liver-specific protein-Tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/- mice. J Biol Chem 2005; 15: 15038-46.
25. Combs AP. Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J Med Chem 2010; 6: 2333-44.
26. He R, Zeng LF, He Y, Zhang ZY. Recent advances in PTP1B inhibitor development for the treatment of type-2 diabetes and obesity. In: Jones RM, editor. New therapeutic strategies for type 2 diabetes: small molecule approaches. London: Royal Society of Chemistry; 2012. p 142-76.
27. Lessard L, Stuible M, Tremblay ML. The two faces of PTP1B in cancer. Biochim Biophys Acta 2010; 1804: 613-9.
28. Bjorge JD, Pang A, Fujita DJ. Identification of protein-Tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J Biol Chem 2000; 52: 41439-46.
29. Dube N, Cheng A, Tremblay ML. The role of protein tyrosine phosphatase 1B in Ras signaling. Proc Natl Acad Sci U S A 2004; 7: 1834-9.
30. Wiener JR, Kerns BJ, Harvey EL, Conaway MR, Iglehart JD, Berchuck A, et al. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst 1994; 5: 372-8.
31. Bentires-Alj M, Neel BG. Protein-Tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res 2007; 6: 2420-4.
32. Julien SG, Dube N, Read M, Penney J, Paquet M, Han YX, et al. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat Genet 2007; 3: 338-46.
33. Chen QT, Li Y, Li Z, Zhao Q, Fan LQ. Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis. J Mol Histol 2014; 2: 153-9.
34. Freeman RM, Plutzky J, Neel BG. Identification of a human src homology 2-containing protein-Tyrosine-phosphatase-A putative homolog of drosophila corkscrew. Proc Natl Acad Sci U S A 1992; 23: 11239-43.
35. Neel BG, Gu HH, Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003; 6: 284-93.
36. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell 1998; 4: 441-50.
37. Klinghoffer RA, Kazlauskas A. Identification of a putative syp substrate, the pdgf-beta receptor. J Biol Chem 1995; 38: 22208-17.
38. Ren Y, Meng SS, Mei L, Zhao ZJ, Jove R, Wu J. Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J Biol Chem 2004; 9: 8497-505.
39. Hanafusa H, Torii S, Yasunaga T, Matsumoto K, Nishida E. Shp2, an SH2-containing protein-Tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor sprouty. J Biol Chem 2004; 22: 22992-5.
40. Jarvis LA, Toering SJ, Simon MA, Krasnow MA, Smith-Bolton RK. Sprouty proteins are in vivo targets of Corkscrew/SHP-2 tyrosine phosphatases. Development 2006; 6: 1133-42.
41. Li W, Nishimura R, Kashishian A, Batzer AG, Kim WJH, Cooper JA, et al. A new function for a phosphotyrosine phosphatase - linking grb2- sos to a receptor tyrosine kinase. Mol Cell Biol 1994; 1: 509-17.
42. Zhang SQ, Tsiaras WG, Araki T, Wen GY, Minichiello L, Klein R, et al. Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2. Mol Cell Biol 2002; 12: 4062-72.
43. Mattoon DR, Lamothe B, Lax I, Schlessinger J. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI- 3K/Akt cell survival pathway. BMC Biol 2004; 2: 24.
44. Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 2008; 2: 179-92.
45. Chan RJ, Feng GS. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 2007; 3: 862-7.
46. Miyamoto D, Miyamoto M, Takahashi A, Yomogita Y, Higashi H, Kondo S, et al. Isolation of a distinct class of gain-of-function SHP- 2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene 2008; 25: 3508-15.
47. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 2004; 8: 849-57.
48. Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang WT, Mohi MG, et al. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-Autonomous effects on multiple stages of hematopoiesis. Blood 2009; 18: 4414-24.
49. Emanuel PD, Shannon KM, Castleberry RP. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Mol Med Today 1996; 11: 468-75.
50. Chan RJ, Leedy MB, Munugalavadla V, Voorhorst CS, Li YJ, Yu MG, et al. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood 2005; 9: 3737-42.
51. Yang ZY, Li YP, Yin FQ, Chan RJ. Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival. Exp Hematol 2008; 10: 1285-96.
52. Zhang X, He YT, Liu SJ, Yu ZH, Jiang ZX, Yang ZY, et al. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J Med Chem 2010; 6: 2482-93.
53. Liu W, Yu B, Xu G, Xu WR, Loh ML, Tang LD, et al. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). J Med Chem 2013; 18: 7212-21.
54. Yu B, Liu W, Yu WM, Loh ML, Alter S, Guvench O, et al. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11- associated malignancies. Mol Cancer Ther 2013; 9: 1738-48.
55. Mali RS, Ma PL, Zeng LF, Martin H, Ramdas B, He YT, et al. Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT. Blood 2012; 13: 2669-78.
56. Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 2012; 4: 529-37.
57. Xu J, Zeng LF, Shen WH, Turchi JJ, Zhang ZY. Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma. Biochem Biophys Res Commun 2013; 4: 586-90.
58. Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM. Cloning and characterization of a lymphoid-specific, inducible human protein tyrosine phosphatase, Lyp. Blood 1999; 6: 2013-24.
59. Mustelin T, Vang T, Bottini N. Protein tyrosine phosphatases and the immune response. Nat Rev Immunol 2005; 1: 43-57.
60. Vang T, Miletic AV, Arimura Y, Tautz L, Rickert RC, Mustelin T. Protein tyrosine phosphatases in autoimmunity. Annu Rev Immunol Palo Alto: Annual Reviews; 2008. p 29-55.
61. Fousteri G, Liossis SNC, Battaglia M. Roles of the protein tyrosine phosphatase PTPN22 in immunity and autoimmunity. Clin Immunol 2013; 3: 556-65.
62. Cloutier JF, Veillette A. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 1999; 1: 111-21.
63. Gjorloff-Wingren A, Saxena M, Williams S, Hammi D, Mustelin T. Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur J Immunol 1999; 12: 3845-54.
64. Cloutier JF, Veillette A. Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. EMBO J 1996; 18: 4909-18.
65. Gregorieff A, Cloutier JF, Veillette A. Sequence requirements for association of protein-Tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk). J Biol Chem 1998; 21: 13217-22.
66. Ghose R, Shekhtman A, Goger MJ, Ji H, Cowburn D. A novel, specific interaction involving the Csk SH3 domain and its natural ligand. Nat Struct Biol 2001; 11: 998-1004.
67. Hasegawa K, Martin F, Huang GM, Tumas D, Diehl L, Chan AC. PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 2004; 5658: 685-9.
68. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 4: 337-8.
69. Pei Z, Chen X, Sun C, Du H, Wei H, Song W, et al. A novel single nucleotide polymorphism in the protein tyrosine phosphatase N22 gene (PTPN22) is associated with type 1 diabetes in a Chinese population. Diabet Med 2014; 2: 219-26.
70. Begovich AB, Carlton VEH, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 2: 330-7.
71. Lee AT, Li W, Liew A, Bombardier C, Weisman M, Massarotti EM, et al. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLASE status. Genes Immun 2005; 2: 129-33.
72. Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, Howson JMM, et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004; 11: 3020-3.
73. Velaga MR, Wilson V, Jennings CE, Owen CJ, Herington S, Donaldson PT, et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J Clin Endocrinol Metab 2004; 11: 5862-5.
74. Vandiedonck C, Capdevielle C, Giraud M, Krumeich S, Jais JP, Eymard B, et al. Association of the PTPN22∗R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol 2006; 2: 404-7.
75. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VEH, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004; 3: 504-7.
76. Vang T, Congia M, Macis MD, Musumeci L, Orru V, Zavattari P, et al. Autoimmune-Associated lymphoid tyrosine phosphatase is a gain-offunction variant. Nat Genet 2005; 12: 1317-9.
77. Vang T, Liu WH, Delacroix L, Wu SD, Vasile S, Dahl R, et al. LYP inhibits T-cell activation when dissociated from CSK. Nat Chem Biol 2012; 5: 437-46.
78. Zhang JY, Zahir N, Jiang QH, Miliotis H, Heyraud S, Meng XW, et al. The autoimmune disease-Associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 2011; 9: 902-U122.
79. Dai XZ, James RG, Habib T, Singh S, Jackson S, Khim S, et al. A disease-Associated PTPN22 variant promotes systemic autoimmunity in murine models. J Clin Invest 2013; 5: 2024-36.
80. Stanford SM, Krishnamurthy D, Falk MD, Messina R, Debnath B, Li S, et al. Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells. J Med Chem 2011; 6: 1640-54.
81. Krishnamurthy D, Karver MR, Fiorillo E, Orru V, Stanford SM, Bottini N, et al. Gold(I)-mediated inhibition of protein tyrosine phosphatases: A detailed in vitro and cellular study. J Med Chem 2008; 15: 4790-5.
82. He YT, Liu SJ, Menon A, Stanford S, Oppong E, Gunawan AM, et al. A potent and selective small-molecule inhibitor for the lymphoidspecific tyrosine phosphatase (LYP), a target associated with autoimmune diseases. J Med Chem 2013; 12: 4990-5008.
83. Andersson LC, Karhi KK, Gahmberg CG, Rodt H. Molecular identification of T cell-specific antigens on human T lymphocytes and thymocytes. Eur J Immunol 1980; 5: 359-62.
84. Omary MB, Trowbridge IS, Battifora HA. Human homologue of murine T200 glycoprotein. J Exp Med 1980; 4: 842-52.
85. Hermiston ML, Xu Z, Weiss A. CD45: A critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 2003; 21: 107-37.
86. Desai DM, Sap J, Silvennoinen O, Schlessinger J, Weiss A. The catalytic activity of the cd45 membrane-proximal phosphatase domain is required for TCR signaling and regulation. EMBO J 1994; 17: 4002-10.
87. Trowbridge IS, Thomas ML. CD45 - an emerging role as a proteintyrosine- phosphatase required for lymphocyte-Activation and development. Annu Rev Immunol 1994; 12: 85-116.
88. Thomas ML. The leukocyte common antigen family. Annu Rev Immunol 1989; 7: 339-69.
89. Ashwell JD, D'Oro U. CD45 and Src-family kinases: and now for something completely different. Immunol Today 1999; 9: 412-6.
90. Thomas ML, Brown EJ. Positive and negative regulation of Src-family membrane kinases by CD45. Immunol Today 1999; 9: 406-11.
91. Alexander DR. The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function. Semin Immunol 2000; 4: 349-59.
92. McFarland EDC, Hurley TR, Pingel JT, Sefton BM, Shaw A, Thomas ML. Correlation between src family member regulation by the protein-Tyrosine-phosphatase cd45 and transmembrane signaling through the T-cell receptor. Proc Natl Acad Sci U S A 1993; 4: 1402-6.
93. Sieh M, Bolen JB, Weiss A. CD45 specifically modulates binding of Lck to a phosphopeptide encompassing the negative regulatory tyrosine of LCK. EMBO J 1993; 1: 315-21.
94. Stone JD, Conroy LA, Byth KF, Hederer RA, Howlett S, Takemoto Y, et al. Aberrant TCR-mediated signaling in CD45-null thymocytes involves dysfunctional regulation of Lck, Fyn, TCR-zeta and ZAP-70. J Immunol 1997; 12: 5773-82.
95. Seavitt JR, White LS, Murphy KM, Loh DY, Perlmutter RM, Thomas ML. Expression of the p56(lck) Y505F mutation in CD45-deficient mice rescues thymocyte development. Mol Cell Biol 1999; 6: 4200-8.
96. Burns CM, Sakaguchi K, Appella E, Ashwell JD. CD45 regulation of tyrosine phosphorylation and enzyme-Activity of src family kinases. J Biol Chem 1994; 18: 13594-600.
97. D'Oro U, Ashwell JD. Cutting edge: The CD45 tyrosine phosphatase is an inhibitor of Lck activity in thymocytes. J Immunol 1999; 4: 1879-83.
98. McNeill L, Salmond RJ, Cooper JC, Carret CK, Cassady-Cain RL, Roche-Molina M, et al. The differential regulation of lck kinase phosphorylation sites by CD45 is critical for T cell receptor signaling responses. Immunity 2007; 3: 425-37.
99. Katagiri T, Ogimoto M, Hasegawa K, Mizuno K, Yakura H. Selective regulation of lyn tyrosine kinase by CD45 in immature B-cells. J Biol Chem 1995; 47: 27987-90.
100. Yanagi S, Sugawara H, Kurosaki M, Sabe H, Yamamura H, Kurosaki T. CD45 modulates phosphorylation of both autophosphorylation and negative regulatory tyrosines of Lyn in B cells. J Biol Chem 1996; 48: 30487-92.
101. Katagiri T, Ogimoto M, Hasegawa K, Arimura Y, Mitomo K, Okada M, et al. CD45 negatively regulates Lyn activity by dephosphorylating both positive and negative regulatory tyrosine residues in immature B cells. J Immunol 1999; 3: 1321-6.
102. Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Welstead G, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 2001; 6818: 349-54.
103. Roach T, Slater S, Koval M, White L, McFarland EC, Okumura M, et al. CD45 regulates Src family member kinase activity associated with macrophage integrin-mediated adhesion. Curr Biol 1997; 6: 408-17.
104. Trop S, Charron J, Arguin C, Hugo P. Thymic selection generates T cells expressing self-reactive TCRs in the absence of CD45. J Immunol 2000; 6: 3073-9.
105. Tchilian EZ, Beverley PCL. Altered CD45 expression and disease. Trends Immunol 2006; 3: 146-53.
106. Jacobsen M, Schweer D, Ziegler A, Gaber R, Schock S, Schwinzer R, et al. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet 2000; 4: 495-9.
107. Ballerini C, Rosati E, Salvetti M, Ristori G, Cannoni S, Biagioli T, et al. Protein tyrosine phosphatase receptor-Type C exon 4 gene mutation distribution in an Italian multiple sclerosis population. Neurosci Lett 2002; 3: 325-7.
108. Vyshkina T, Leist TP, Shugart YY, Kalman B. CD45 (PTPRC) as a candidate gene in multiple sclerosis. Mult Scler 2004; 6: 614-7.
109. Tchilian EZ, Wallace DL, Dawes R, Imami N, Burton C, Gotch F, et al. A point mutation in CD45 may be associated with an increased risk of HIV-1 infection. AIDS 2001; 14: 1892-4.
110. Vogel A, Strassburg CP, Manns MP. 77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link. Genes Immun 2003; 1: 79-81.
111. Schwinzer R, Witte T, Hundrieser J, Ehlers S, Momot T, Hunzelmann N, et al. Enhanced frequency of a PTPRC (CD45) exon A mutation (77C?G) in systemic sclerosis. Genes Immun 2003; 2: 168-9.
112. Lynch KW, Weiss A. A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer. J Biol Chem 2001; 26: 24341-7.
113. Jacobsen M, Hoffmann S, Cepok S, Stei S, Ziegler A, Sommer N, et al. A novel mutation in PTPRC interferes with splicing and alters the structure of the human CD45 molecule. Immunogenetics 2002; 3: 158-63.
114. Stanton T, Boxall S, Hirai K, Dawes R, Tonks S, Yasui T, et al. A highfrequency polymorphism in exon 6 of the CD45 tyrosine phosphatase gene (PTPRC) resulting in altered isoform expression. Proc Natl Acad Sci U S A 2003; 10: 5997-6002.
115. Boxall S, Stanton T, Hirai K, Ward V, Yasui T, Tahara H, et al. Disease associations and altered immune function in CD45 138G variant carriers. Hum Mol Genet 2004; 20: 2377-84.
116. Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, et al. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 2000; 7: 1059-70.
117. Nemecek ER, Matthews DC. Antibody-based therapy of human leukemia. Curr Opin Hematol 2002; 4: 316-21.
118. Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Hui TE, et al. Phase I study of 131I-Anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999; 4: 1237-47.
119. Orozco JJ, Back T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur DS, et al. Anti-CD45 radioimmunotherapy using At-211 with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood 2013; 18: 3759-67.
120. Pagel JM, Kenoyer AL, Back T, Hamlin DK, Wilbur DS, Fisher DR, et al. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-Term survival in a mouse myeloid leukemia xenograft model. Blood 2011; 3: 703-11.
121. Banville D, Ahmad S, Stocco R, Shen SH. A novel protein-Tyrosine phosphatase with homology to both the cytoskeletal proteins of the band 4.1 family and junction-Associated guanylate kinases. J Biol Chem 1994; 35: 22320-7.
122. Maekawa K, Imagawa N, Nagamatsu M, Harada S. Molecular-cloning of a novel protein-Tyrosine-phosphatase containing a membranebinding domain and GLGF repeats. FEBS Lett 1994; 2: 200-6.
123. Saras J, Claessonwelsh L, Heldin CH, Gonez LJ. Cloning and characterization of ptpl1, a protein-Tyrosine-phosphatase with similarities to cytoskeletal-Associated proteins. J Biol Chem 1994; 39: 24082-9.
124. Bompard G, Martin M, Roy C, Vignon F, Freiss G. Membrane targeting of protein tyrosine phosphatase PTPL1 through its FERM domain via binding to phosphatidylinositol 4, 5-biphosphate. J Cell Sci 2003; 12: 2519-30.
125. Abaan OD, Toretsky JA. PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev 2008; 2: 205-14.
126. Andersen JN, Mortensen OH, Peters GH, Drake PG, Iversen LF, Olsen OH, et al. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol Cell Biol 2001; 21: 7117-36.
127. Villa F, Deak M, Bloomberg GB, Alessi DR, Van Aalten DMF. Crystal structure of the PTPL1/FAP-1 human tyrosine phosphatase mutated in colorectal cancer - Evidence for a second phosphotyrosine substrate recognition pocket. J Biol Chem 2005; 9: 8180-7.
128. Sato T, Irie S, Kitada S, Reed JC. FAP-1-A protein-Tyrosinephosphatase that associates with FAS. Science 1995; 5209: 411-5.
129. Saras J, Engstrom U, Gonez LJ, Heldin CH. Characterization of the interactions between PDZ domains of the protein-Tyrosine phosphatase PTPL1 and the carboxyl-Terminal tail of Fas. J Biol Chem 1997; 34: 20979-81.
130. Yanagisawa J, Takahashi M, Kanki H, Yano-Yanagisawa H, Tazunoki T, Sawa E, et al. The molecular interaction of Fas and FAP-1 - A tripeptide blocker of human Fas interaction with FAP-1 promotes Fasinduced apoptosis. J Biol Chem 1997; 13: 8539-45.
131. Ivanov VN, Bergami PL, Maulit G, Sato TA, Sassoon D, Ronai Z. FAP- 1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol 2003; 10: 3623-35.
132. Irie S, Hachiya T, Rabizadeh S, Maruyama W, Mukai J, Li Y, et al. Functional interaction of Fas-Associated phosphatase-1 (FAP-1) with p75(NTR) and their effect on NF-kappa B activation. FEBS Lett 1999; 2: 191-8.
133. Erdmann KS, Kuhlmann J, Lessmann V, Herrmann L, Eulenburg V, Muller O, et al. The adenomatous polyposis coli-protein (APC) interacts with the protein tyrosine phosphatase PTP-BL via an alternatively spliced PDZ domain. Oncogene 2000; 34: 3894-901.
134. Maekawa K, Imagawa N, Naito A, Harada S, Yoshie O, Takagi S. Association of protein-Tyrosine phosphatase PTP-BAS with the transcription-factor-inhibitory protein I kappa-B alpha through interaction between the PDZ1 domain and ankyrin repeats. Biochem J 1999; 337: 179-84.
135. Nakai Y, Irie S, Sato TA. Identification of I kappa B alpha as a substrate of Fas-Associated phosphatase-1. Eur J Biochem 2000; 24: 7170-5.
136. Dromard M, Bompard G, Glondu-Lassis M, Puech C, Chalbos D, Freiss G. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res 2007; 14: 6806-13.
137. Zhu JH, Chen R, Yi W, Cantin GT, Fearns C, Yang Y, et al. Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling. Oncogene 2008; 18: 2525-31.
138. Nakahira M, Tanaka T, Robson BE, Mizgerd JP, Grusby MJ. Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL. Immunity 2007; 2: 163-76.
139. Wansink DG, Peters W, Schaafsma I, Sutmuller RPM, Oerlemans F, Adema GJ, et al. Mild impairment of motor nerve repair in mice lacking PTP-BL tyrosine phosphatase activity. Physiol Genomics 2004; 1: 50-60.
140. Lorber B, Hendriks W, Van Der Zee C, Berry M, Logan A. Effects of LAR and PTP-BL phosphatase deficiency on adult mouse retinal cells activated by lens injury. Eur J Neurosci 2005; 9: 2375-83.
141. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, et al. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 1998; 8: 1741-9.
142. Ungefroren H, Kruse ML, Trauzold A, Roeschmann S, Roeder C, Arlt A, et al. FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. J Cell Sci 2001; 15: 2735-46.
143. Meinhold-Heerlein I, Stenner-Liewen F, Liewen H, Kitada S, Krajewska M, Krajewski S, et al. Expression and potential role of Fas-Associated phosphatase-1 in ovarian cancer. Am J Pathol 2001; 4: 1335-44.
144. Yao H, Song E, Chen J, Hamar P. Expression of FAP-1 by human colon adenocarcinoma: implication for resistance against Fas-mediated apoptosis in cancer. Br J Cancer 2004; 9: 1718-25.
145. Wieckowski E, Atarashi Y, Stanson J, Sato TA, Whiteside TL. FAP-1- mediated activation of NF-kappa B induces resistance of head and neck cancer to Fas-induced apoptosis. J Cell Biochem 2007; 1: 16-28.
146. Lee SH, Shin MS, Lee JY, Park WS, Kim SY, Jang JJ, et al. In vivo expression of soluble Fas and Fap-1: Possible mechanisms of Fas resistance in human hepatoblastomas. J Pathol 1999; 2: 207-12.
147. Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS, et al. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 2001; 3: 250-6.
148. Uren A, Toretsky JA. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent. Future Oncol 2005; 4: 521-8.
149. Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's sarcoma tumorigenesis. Oncogene 2005; 16: 2715-22.
150. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001; 6: 673-9.
151. Lessnick SL, Dacwag CS, Golub TR. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002; 4: 393-401.
152. Baer C, Nees M, Breit S, Selle B, Kulozik AE, Schaefer KL, et al. Profiling and functional annotation of MRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma. Int J Cancer 2004; 5: 687-94.
153. Xiao ZY, Wu W, Eagleton N, Chen HQ, Shao J, Teng H, et al. Silencing Fas-Associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin. World J Gastroenterol 2010; 1: 112-8.
154. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001; 10: 912-23.
155. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The mir-200 family and mir-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 5: 593-601.
156. Peter ME. Let-7 and miR-200 microRNAs Guardians against pluripotency and cancer progression. Cell Cycle 2009; 6: 843-52.
157. Schickel R, Park SM, Murmann AE, Peter ME. mir-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell 2010; 6: 908-15.
158. Ying J, Li H, Cui Y, Wong AHY, Langford C, Tao Q. Epigenetic disruption of two proapoptotic genes MAPK10/JNK3 and PTPN13/FAP-1 in multiple lymphomas and carcinomas through hypermethylation of a common bidirectional promoter. Leukemia 2006; 6: 1173-5.
159. Yeh SH, Wu DC, Tsai CY, Kuo TJ, Yu WC, Chang YS, et al. Genetic characterization of Fas-Associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma. Clin Cancer Res 2006; 4: 1097-108.
160. Wang ZH, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004; 5674: 1164-6.
161. Lombroso PJ, Murdoch G, Lerner M. Molecular characterization of a protein-Tyrosine-phosphatase enriched in striatum. Proc Natl Acad Sci U S A 1991; 16: 7242-6.
162. Lombroso PJ, Naegele JR, Sharma E, Lerner M. A protein-Tyrosinephosphatase expressed within dopaminoceptive neurons of the basal ganglia and related structures. J Neurosci 1993; 7: 3064-74.
163. Bult A, Zhao F, Dirkx R, Raghunathan A, Solimena M, Lombroso PJ. STEP: A family of brain-enriched PTPs. Alternative splicing produces transmembrane, cytosolic and truncated isoforms. Eur J Cell Biol 1997; 4: 337-44.
164. Venkitaramani DV, Paul S, Zhang YF, Kurup P, Ding L, Tressler L, et al. Knockout of striatal enriched protein tyrosine phosphatase in mice results in increased ERK1/2 phosphorylation. Synapse 2009; 1: 69-81.
165. Francis DM, Kumar GS, Koveal D, Tortajada A, Page R, Peti W. The differential regulation of p38alpha by the neuronal kinase interaction motif protein tyrosine phosphatases, a detailed molecular study. Structure 2013; 9: 1612-23.
166. Sweatt JD. Mitogen-Activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 2004; 3: 311-7.
167. Cuenda A, Rousseau S. P38 MAP-Kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta-Mol Cell Res 2007; 8: 1358-75.
168. Borders AS, De Almeida L, Van Eldik LJ, Watterson DM. The p38alpha mitogen-Activated protein kinase as a central nervous system drug discovery target. BMC Neurosci 2008; 9 Suppl 2: S12.
169. Zhang Y, Venkitaramani DV, Gladding CM, Zhang YF, Kurup P, Molnar E, et al. The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. J Neurosci 2008; 42: 10561-6.
170. Nguyen TH, Liu J, Lombroso PJ. Striatal enriched phosphatase 61 dephosphorylates Fyn at phosphotyrosine 420. J Biol Chem 2002; 27: 24274-9.
171. Nakazawa T, Komai S, Tezuka T, Hisatsune C, Umemori H, Semba K, et al. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-Aspartate receptor. J Biol Chem 2001; 1: 693-9.
172. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8: 1051-8.
173. Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, Greengard P, et al. Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci 2010; 17: 5948-57.
174. Goebel-Goody SM, Baum M, Paspalas CD, Fernandez SM, Carty NC, Kurup P, et al. Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol Rev 2012; 1: 65-87.
175. Kurup P, Zhang YF, Venkitaramani DV, Xu JA, Lombroso PJ. The role of STEP in Alzheimer's disease. Channels 2010; 5: 347-50.
176. Carty NC, Xu J, Kurup P, Brouillette J, Goebel-Goody SM, Austin DR, et al. The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Transl Psychiatr 2012; 2: e137.
177. Hicklin TR, Wu PH, Radcliffe RA, Freund RK, Goebel-Goody SM, Correa PR, et al. Alcohol inhibition of the NMDA receptor function, long-Term potentiation, and fear learning requires striatal-enriched protein tyrosine phosphatase. Proc Natl Acad Sci U S A 2011; 16: 6650-5.
178. Theodosiou A, Ashworth A. MAP kinase phosphatases. Genome Biol 2002; 3: REVIEWS3009.
179. Charles CH, Abler AS, Lau LF. cDNA sequence of a growth factorinducible immediate early gene and characterization of its encoded protein. Oncogene 1992; 1: 187-90.
180. Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates map kinase in vivo. Cell 1993; 3: 487-93.
181. Wu JJ, Zhang L, Bennett AM. The noncatalytic amino terminus of mitogen-Activated protein kinase phosphatase 1 directs nuclear targeting and serum response element transcriptional regulation. Mol Cell Biol 2005; 11: 4792-803.
182. Guan KL, Butch E. Isolation and characterization of a novel dual specific phosphatase, hvh2, which selectively dephosphorylates the mitogen-Activated protein-kinase. J Biol Chem 1995; 13: 7197-203.
183. Franklin CC, Kraft AS. Conditional expression of the mitogenactivated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-Activated protein kinase in U937 cells. J Biol Chem 1997; 27: 16917-23.
184. Chi HB, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennettt AM, et al. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A 2006; 7: 2274-9.
185. Kondoh K, Nishida E. Regulation of MAP kinases by MAP kinase phosphatases. Biochim Biophys Acta-Mol Cell Res 2007; 8: 1227
186. Dor fman K, Carrasco D, Gruda M, Ryan C, Lira SA, Bravo R. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 1996; 5: 925-31.
187. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 2008; 2: 253-61.
188. Lawan A, Shi H, Gatzke F, Bennett AM. Diversity and specificity of the mitogen-Activated protein kinase phosphatase-1 functions. Cell Mol Life Sci 2013; 2: 223-37.
189. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, et al. Expression of mitogen-Activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 1996; 5: 1553-64.
190. Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, Capodieci P, et al. Mitogen-Activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest 1997; 1: 37-51.
191. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, et al. Gene expression profiles in normal and cancer cells. Science 1997; 5316: 1268-72.
192. Magi-Galluzzi C, Montironi R, Cangi MG, Wishnow K, Loda M. Mitogen-Activated protein kinases and apoptosis in PIN. Virchows Arch Int J Pathol 1998; 5: 407-13.
193. Denkert C, Schmitt WD, Berger S, Reles A, Pest S, Siegert A, et al. Expression of mitogen-Activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer 2002; 5: 507-13.
194. Vicent S, Garayoa M, Lopez-Picazo JM, Lozano MD, Toledo G, Thunnissen F, et al. Mitogen-Activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 2004; 11: 3639-49.
195. Srikanth S, Franklin CC, Duke RC, Kraft AS. Human DU145 prostate cancer cells overexpressing mitogen-Activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol Cell Biochem 1999; 1-2: 169-78.
196. Small GW, Shi YY, Higgins LS, Orlowski RZ. Mitogen-Activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 2007; 9: 4459-66.
197. Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ. Evidence that mitogen-Activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 2004; 6: 1478-90.
198. Rojo F, Gonzalez-Navarrete I, Bragado R, Dalmases A, Menendez S, Cortes-Sempere M, et al. Mitogen-Activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin Cancer Res 2009; 10: 3530-9.
199. Chattopadhyay S, Machado-Pinilla R, Manguan-Garcia C, Belda- Iniesta C, Moratilla C, Cejas P, et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 2006; 23: 3335-45.
200. Valjent E, Caboche J, Vanhoutte P. Mitogen-Activated protein kinase/extracellular signal-regulated kinase induced gene regulation in brain - A molecular substrate for learning and memory?. Mol Neurobiol 2001; 2-3: 83-99.
201. Kristiansen M, Hughes R, Patel P, Jacques TS, Clark AR, Ham J. Mkp1 is a c-jun target gene that antagonizes jnk-dependent apoptosis in sympathetic neurons. J Neurosci 2010; 32: 10820-32.
202. Jeanneteau F, Deinhardt K. Fine-Tuning MAPK signaling in the brain: The role of MKP-1. Commun Integr Biol 2011; 3: 281-3.
203. Jeanneteau F, Deinhardt K, Miyoshi G, Bennett AM, Chao MV. The MAP kinase phosphatase MKP-1 regulates BDNF-induced axon branching. Nat Neurosci 2010; 11: 1373-79.
204. Duric V, Banasr M, Licznerski P, Schmidt HD, Stockmeier CA, Simen AA, et al. A negative regulator of MAP kinase causes depressive behavior. Nat Med 2010; 11: 1328-32.
205. Stephens BJ, Han HY, Gokhale V, Von Hoff DD. PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther 2005; 11: 1653-61.
206. Zeng Q, Si XN, Horstmann H, Xu Y, Hong WJ, Pallen CJ. Prenylationdependent association of protein-Tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. J Biol Chem 2000; 28: 21444-52.
207. Sun JP, Wang WQ, Yang H, Liu SJ, Liang F, Fedorov AA, et al. Structure and biochemical properties of PRL-1, a phosphatase implicated in cell growth, differentiation, and tumor invasion. Biochemistry 2005; 36: 12009-21.
208. Achiwa H, Lazo JS. PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Res 2007; 2: 643-50.
209. Liang FB, Liang J, Wang WQ, Sun AP, Udho E, Zhang ZY. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem 2007; 8: 5413-9.
210. Wang Y, Lazo JS. Metastasis-Associated phosphatase PRL-2 regulates tumor cell migration and invasion. Oncogene 2012; 7: 818-27.
211. Min SH, Kim DM, Heo YS, Kim YI, Kim HM, Kim J, et al. New p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53. Oncogene 2009; 4: 545-54.
212. Min SH, Kim DM, Heo YS, Kim HM, Kim IC, Yoo OJ. Downregulation of p53 by phosphatase of regenerating liver 3 is mediated by MDM2 and PIRH2. Life Sci 2010; 1-2: 66-72.
213. Luo Y, Liang FB, Zhang ZY. PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry 2009; 8: 1838-46.
214. Peng L, Xing X, Li W, Qu L, Meng L, Lian S, et al. PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling. Mol Cancer 2009; 8: 110.
215. Bessette DC, Qiu DX, Pallen CJ. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev 2008; 2: 231-52.
216. Campbell AM, Zhang ZY. Phosphatase of regenerating liver: a novel target for cancer therapy. Expert Opin Ther Targets 2014; 5: 555-69.
217. Stephens B, Han HY, Hostetter G, Demeure MJ, Von Hoff DD. Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells. Mol Cancer Ther 2008; 1: 202-10.
218. Nakashima M, Lazo JS. Phosphatase of regenerating liver-1 promotes cell migration and invasion and regulates filamentous actin dynamics. J Pharmacol Exp Ther 2010; 2: 627-33.
219. Yagi T, Morimoto A, Eguchi M, Hibi S, Sako M, Ishii E, et al. Identification of a gene expression signature associated with pediatric AML prognosis. Blood 2003; 5: 1849-56.
220. Hardy S, Wong NN, Muller WJ, Park M, Tremblay ML. Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast tumor formation and progression. Cancer Res 2010; 21: 8959-67.
221. Rios P, Li X, Kohn M. Molecular mechanisms of the PRL phosphatases. FEBS J 2013; 2: 505-24.
222. Peng LR, Ning JY, Meng L, Shou CC. The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol 2004; 9: 521-6.
223. Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, et al. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 2003; 11: 2716-22.
224. Kato H, Semba S, Miskad UA, Seo Y, Kasuga M, Yokozaki H. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res 2004; 21: 7318-28.
225. Rouleau C, Roy A, St Martin T, Dufault MR, Boutin P, Liu DP, et al. Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function. Mol Cancer Ther 2006; 2: 219-29.
226. Walls CD, Iliuk A, Bai YP, Wang M, Tao WA, Zhang ZY. Phosphatase of regenerating liver 3 (PRL3) provokes a tyrosine phosphoproteome to drive prometastatic signal transduction. Mol Cell Proteomics 2013; 12: 3759-77.
227. Al-Aidaroos AQO, Yuen HF, Guo K, Zhang SD, Chung TH, Chng WJ, et al. Metastasis-Associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest 2013; 8: 3459-71.
228. Dong YS, Zhang LJ, Zhang S, Bai YP, Chen HY, Sun XX, et al. Phosphatase of regenerating liver 2 (PRL2) is essential for placental development by down-regulating PTEN (phosphatase and tensin homologue deleted on chromosome 10) and activating AKT protein. J Biol Chem 2012; 38: 32172-79.
229. Dong YS, Zhang LJ, Bai YP, Zhou HM, Campbell AM, Chen HY, et al. Phosphatase of regenerating liver 2 (PRL2) deficiency impairs kit signaling and spermatogenesis. J Biol Chem 2014; 6: 3799-810.
230. Kobayashi M, Bai Y, Dong Y, Yu H, Chen S, Gao R, et al. PRL2/PTP4A2 phosphatase is important for hematopoietic stem cell selfrenewal. Stem Cells 2014; 32: 1956-67.
231. Ramponi G, Stefani M. Structural, catalytic, and functional properties of low M-r phosphotyrosine protein phosphatases. Evidence of a long evolutionary history. Int J Biochem Cell Biol 1997; 2: 279-92.
232. Dissing J, Johnsen AH, Sensabaugh GF. Human red-cell acidphosphatase (ACP1) - the amino-Acid-sequence of the 2 isozymes BF and BS encoded by the acp1-star-b allele. J Biol Chem 1991; 31: 20619-25.
233. Wo YYP, McCormack AL, Shabanowitz J, Hunt DF, Davis JP, Mitchell GL, et al. Sequencing, cloning, and expression of human red celltype acid-phosphatase, a cytoplasmic phosphotyrosyl protein phosphatase. J Biol Chem 1992; 15: 10856-65.
234. Zhang M, Stauffacher CV, Lin DY, Van Etten RL. Crystal structure of a human low molecular weight phosphotyrosyl phosphatase - Implications for substrate specificity. J Biol Chem 1998; 34: 21714-20.
235. Chiarugi P, Cirri P, Raugei G, Camici G, Dolfi F, Berti A, et al. PDGF receptor as a specific in vivo target for low m(r) phosphotyrosine protein phosphatase. FEBS Lett 1995; 1: 49-53.
236. Chiarugi P, Cirri P, Raugei G, Manao G, Taddei L, Ramponi G. Low M(r) phosphotyrosine protein phosphatase interacts with the PDGF receptor directly via its catalytic site. Biochem Biophys Res Commun 1996; 1: 21-5.
237. Chiarugi P, Cirri P, Taddei ML, Giannoni E, Fiaschi T, Buricchi F, et al. Insight into the role of low molecular weight phosphotyrosine phosphatase (LAM-PTP) on platelet-derived growth factor receptor (PDGF-r) signaling - LMW-PTP controls PDGF-r kinase activity through TYR- 857 dephosphorylation. J Biol Chem 2002; 40: 37331-8.
238. Chiarugi P, Cirri P, Marra F, Raugei G, Fiaschi T, Camici G, et al. The Src and signal transducers and activators of transcription pathways as specific targets for low molecular weight phosphotyrosine-protein phosphatase in platelet-derived growth factor signaling. J Biol Chem 1998; 12: 6776-85.
239. Zambuzzi WF, Granjeiro JM, Parikh K, Yuvaraj S, Peppelenbosch MP, Ferreira CV. Modulation of Src activity by Low molecular weight protein tyrosine phosphatase during osteoblast differentiation. Cell Physiol Biochem 2008; 5-6: 497-506.
240. Rigacci S, Guidotti V, Parri M, Berti A. Modulation of STAT5 interaction with LMW-PTP during early megakaryocyte differentiation. Biochemistry 2008; 6: 1482-9.
241. Rigacci S, Rovida E, Dello Sbarba P, Berti A. Low Mr phosphotyrosine protein phosphatase associates and dephosphorylates p125 focal adhesion kinase, interfering with cell motility and spreading. J Biol Chem 2002; 44: 41631-6.
242. Chiarugi P, Cirri P, Taddei L, Giannoni E, Camici G, Manao G, et al. The low M(r) protein-Tyrosine phosphatase is involved in Rhomediated cytoskeleton rearrangement after integrin and plateletderived growth factor stimulation. J Biol Chem 2000; 7: 4640-6.
243. Kikawa KD, Vidale DR, Van Etten RL, Kinch MS. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 2002; 42: 39274-9.
244. Chiarugi P, Taddei ML, Schiavone N, Papucci L, Giannoni E, Fiaschi T, et al. LMW-PTP is a positive regulator of tumor onset and growth. Oncogene 2004; 22: 3905-14.
245. Parri M, Buricchi F, Taddei ML, Giannoni E, Raugei G, Ramponi G, et al. EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase. J Biol Chem 2005; 40: 34008-18.
246. Zantek ND, Azimi M, Fedor-Chaiken M, Wang BC, Brackenbury R, Kinch MS. E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 1999; 9: 629-38.
247. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 5: 2301-6.
248. Chiarugi P, Cirri P, Marra F, Raugei G, Camici G, Manao G, et al. LMWPTP is a negative regulator of insulin-mediated mitotic and metabolic signalling. Biochem Biophys Res Commun 1997; 2: 676-82.
249. Pandey SK, Yu XX, Watts LM, Michael MD, Sloop KW, Rivard AR, et al. Reduction of low molecular weight protein-Tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. J Biol Chem 2007; 19: 14291-9.
250. Bottini N, MacMurray J, Peters W, Rostamkhani M, Comings DE. Association of the acid phosphatase (ACP1) gene with triglyceride levels in obese women. Mol Genet Metab 2002; 3: 226-9.
251. Bottini N, Bottini E, Gloria-Bottini F, Mustelin T. Low-molecular-weight protein tyrosine phosphatase and human disease: in search of biochemical mechanisms. Arch Immunol Ther Exp (Warsz) 2002; 2: 95-104.
252. Sadhu K, Reed SI, Richardson H, Russell P. Human homolog of fission yeast CDC25 mitotic inducer is predominantly expressed in G2. Proc Natl Acad Sci U S A 1990; 13: 5139-43.
253. Galaktionov K, Beach D. Specific activation of CDC25 tyrosine phosphatases by B-Type cyclins - evidence for multiple roles of mitotic cyclins. Cell 1991; 6: 1181-94.
254. Nagata A, Igarashi M, Jinno S, Suto K, Okayama H. An additional homolog of the fission yeast CDC25+ gene occurs in humans and is highly expressed in some cancer-cells. New Biol 1991; 10: 959-68.
255. Lyon MA, Ducruet AP, Wipf P, Lazo JS. Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov 2002; 12: 961-76.
256. Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol 2004; 8: 1043-51.
257. Karisson-Rosenthal C, Millar JBA. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol 2006; 6: 285-92.
258. Hoffmann I, Draetta G, Karsenti E. Activation of the phosphataseactivity of human CDC25A by a CDK2 cyclin-E dependent phosphorylation at the G(1)/S transition. EMBO J 1994; 18: 4302-10.
259. Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H, et al. CDC25A is a novel phosphatase functioning early in the cell-cycle. EMBO J 1994; 7: 1549-56.
260. Blomberg I, Hoffmann I. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin Eand cyclin A-dependent kinases. Mol Cell Biol 1999; 9: 6183-94.
261. Gabrielli BG, DeSouza CPC, Tonks ID, Clark JM, Hayward NK, Ellem KAO. Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J Cell Sci 1996; 109: 1081-93.
262. De Souza CPC, Ellem KAO, Gabrielli BG. Centrosomal and cytoplasmic cdc2/cyclin B1 activation precedes nuclear mitotic events. Exp Cell Res 2000; 1: 11-21.
263. Lindqvist A, Kallstrom H, Lundgren A, Barsoum E, Rosenthal CK. Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1-Cdk1 at the centrosome. J Cell Biol 2005; 1: 35-45.
264. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players?. Good targets?. Nat Rev Cancer 2007; 7: 495-507.
265. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, et al. CDC25 phosphatases as potential human oncogenes. Science 1995; 5230: 1575-7.
266. Ma ZQ, Chua SS, DeMayo FJ, Tsai SY. Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B. Oncogene 1999; 32: 4564-76.
267. Yao Y, Slosberg ED, Wang L, Hibshoosh H, Zhang YJ, Xing WQ, et al. Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice. Oncogene 1999; 37: 5159-66.
268. Brezak MC, Quaranta M, Contour-Galcera MO, Lavergne O, Mondesert O, Auvray P, et al. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases. Mol Cancer Ther 2005; 9: 1378-87.
269. He YT, Zeng LF, Yu ZH, He RJ, Liu SJ, Zhang ZY. Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors. Biorg Med Chem 2012; 6: 1940-6.
270. Wiesmann C, Barr KJ, Kung J, Zhu J, Erlanson DA, Shen W, et al. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol 2004; 8: 730-7.
271. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ. Role of quinones in toxicology. Chem Res Toxicol 2000; 3: 135-60.
272. Monks TJ, Jones DC. The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-Thioethers. Curr Drug Metab 2002; 4: 425-38.
273. Barf T, Kaptein A. Irreversible protein kinase inhibitors: balancing the benefits and risks. J Med Chem 2012; 14: 6243-62.
274. Sanderson K. Irreversible kinase inhibitors gain traction. Nat Rev Drug Discov 2013; 9: 649-51.
275. Rondinone CM, Trevillyan JM, Clampit J, Gum RJ, Berg C, Kroeger P, et al. Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes 2002; 8: 2405-11.
276. Zinker BA, Rondinone CM, Trevillyan JM, Gum RJ, Clampit JE, Waring JF, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A 2002; 17: 11357-62.
277. He R, Zeng LF, He Y, Zhang S, Zhang ZY. Small molecule tools for functional interrogation of protein tyrosine phosphatases. FEBS J 2013; 280: 731-50.